SCHEMBL109314

SCHEMBL109314

COC(=O)c1cc(-c2ccc3c(cnn3C)c2)nc2c3ccc(Cl)cc3n(Cc3ccc(C)cc3)c12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 6/20 0.42
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
PLA2G2A P14555 1/20 0.37
DRD2 P14416 1/20 0.37
TBXA2R P21731 1/20 0.37
PDE1C Q14123 1/20 0.36
DHODH Q02127 2/20 0.36
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
PTGER4 P35408 1/20 0.35
TGFBR1 P36897 1/20 0.34
MAPK14 Q16539 1/20 0.34
SYK P43405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142075 0.93 PLA2G2A (0.46) CACNA1HGAAMAPTLMNAPLA2G2A
SCHEMBL109351 0.87 L3MBTL1 (0.41) GAANPSR1L3MBTL1MAPTLMNA
SCHEMBL178706 0.84 CACNA1H (0.44) CACNA1HGAAMAPTPLA2G2AKMT2A
SCHEMBL110326 0.83 P2RX3 (0.40) GAANPSR1L3MBTL1MAPTLMNA
SCHEMBL143205 0.80 PLA2G2A (0.49) GAAMAPTLMNAPLA2G2ADRD2
SCHEMBL110330 0.79 L3MBTL1 (0.46) GAANPSR1L3MBTL1MAPTLMNA
SCHEMBL170380 0.78 PDE1B (0.41) CACNA1H
SCHEMBL141523 0.77 PLA2G2A (0.47) MAPTLMNAPLA2G2ADHODHMEN1
SCHEMBL145790 0.72 CCR2 (0.46) GAAMAPTLMNAPLA2G2ATBXA2R
SCHEMBL110219 0.70 P2RX3 (0.39) GAANPSR1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 CACNA1H 4219/4885GAA 1883/4885NPSR1 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.